Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Timothy K. MacLachlan"'
Autor:
Timothy K. MacLachlan, Mark N. Milton, Oliver Turner, Francis Tukov, Vivian W. Choi, Jan Penraat, Marie-Hélène Delmotte, Lydia Michaut, Bruce D. Jaffee, Chad E. Bigelow
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 8, Iss C, Pp 105-120 (2018)
Retinitis pigmentosa is a form of retinal degeneration usually caused by genetic mutations affecting key functional proteins. We have previously demonstrated efficacy in a mouse model of RLBP1 deficiency with a self-complementary AAV8 vector carrying
Externí odkaz:
https://doaj.org/article/7326adf338ee446f8ac97a123971d3ee
Autor:
Jeffrey S. Moffit, Diann L. Blanset, Jessica L. Lynch, Timothy K. MacLachlan, Kathleen E. Meyer, Rafael Ponce, Laurence O. Whiteley
Publikováno v:
Human gene therapy. 33(21-22)
The nonclinical safety assessments for gene therapies are evolving, leveraging over 20 years of experimental and clinical experience. Despite the growing experience with these therapeutics, there are no approved harmonized global regulatory documents
Autor:
Yi Liu, Vionnie W. Yu, Qi Zhang, Madhura Panditrao, Yi Yang, Alberto Del Rio-Espinola, Daher Ibrahim Aibo, Azeddine Elhajouji, Konrad Mueller, Karin Abitorabi, Daniel O'Connell, Bo Han, Nishit Patel, Carsten Russ, Craig Mickanin, Timothy K. MacLachlan, Susan C. Stevenson
Publikováno v:
Blood. 140:12982-12983
Autor:
Peter Ulrich, Michael W. Bolt, Antonio R. Fernández de Henestrosa, Claudette L. Fuller, Prathap Kumar S. Mahalingaiah, David R. Compton, Laurence O. Whiteley, Jessica L. Lynch, Brian Lauritzen, Timothy K. MacLachlan, Binu K. Philip
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss, Pp 89-98 (2020)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Nonclinical development strategies for gene therapies are unique from other modalities. The European Federation of Pharmaceutical Industries and Associates (EFPIA) Gene Therapy Working Group surveyed EFPIA member and nonmember pharmaceutical and biot
Publikováno v:
Cell and Gene Therapy Insights
Autor:
M. Di Piazza, H. Bando, Yoji Sato, J.W. van der Laan, W. Shingleton, Shawna Jackman, Giulia Leoni, Michaela Sharpe, S. Libertini, J.W. McBlane, L. Pereira Mouriès, Timothy K. MacLachlan, G. Gowing, B. Surmacz-Cordle, Carla Herberts, K. Yamamoto
Publikováno v:
Cytotherapy. 21:1095-1111
Pluripotent stem cells offer the potential for an unlimited source for cell therapy products. However, there is concern regarding the tumorigenicity of these products in humans, mainly due to the possible unintended contamination of undifferentiated
Publikováno v:
Translational Medicine ISBN: 9781003124542
Translational Medicine
Translational Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcb72b56ca05a074a13654abda8801d8
https://doi.org/10.1201/9781003124542-32
https://doi.org/10.1201/9781003124542-32
Publikováno v:
Current Topics in Nonclinical Drug Development ISBN: 9780429027536
Current Topics in Nonclinical Drug Development
Current Topics in Nonclinical Drug Development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46b838d07c44e39a1d4dc3dc73300c7c
https://doi.org/10.1201/9780429027536-5
https://doi.org/10.1201/9780429027536-5
Autor:
Andrea Kiessling, Frederic Brouta, Wendy J. Freebern, Marlowe J. Schneidkraut, Timothy K. MacLachlan, Birgit Fogal, Shawn Jay Berens, Sven Kronenberg, Curtis Maier, Laura Andrews, Cris Kamperschroer, Danuta J. Herzyk, Nikki Marshall
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 119
With the growth of monoclonal antibodies and other proteins as major modalities in the pharmaceutical industry, there has been an increase in pharmacology and toxicity testing of biotherapeutics in animals. Animals frequently mount an immune response
Autor:
Diann Blanset, Maggie Dempster, Renaud Fleurance, Esther Sutter, Michael W. Leach, Timothy K. MacLachlan, Elizabeth Galbreath, Kathleen M. Heinz-Taheny, Laura Andrews, Anna Maria Giusti, Mary Ellen Cosenza, Joy A. Cavagnaro, Shari A. Price
Publikováno v:
Regulatory Toxicology and Pharmacology. 121:104872
Monoclonal antibodies (mAbs) and mAb derivatives have become mainstay pharmaceutical modalites. A critical assessment is to ascertain the specificity of these molecules prior to human clinical trials. The primary technique for determining specificity